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there is substantial evidence that palliative RT is effective 
with reported response rates varying from 50% to 100%, the 
optimal RT schedule is unclear. This study explores the 
current pattern of practice of palliative RT for bleeding 
tumors with regard to dose and fractionation schemes in the 
Netherlands.  
Materials and Methods: An internet based survey, including 
respondent characteristics, factors influencing the choice of 
RT schedules, expected effectiveness of RT and five patient 
case scenarios on hematemesis, hemoptysis, hematuria, 
rectal bleeding and vaginal bleeding were developed and sent 
to all members (radiation oncologists and residents) of the 
Dutch Society for Radiation Oncology. Descriptive statistics 
were used to evaluate the results 
Results: The response rate of the internet based survey was 
125/374 (34%), and included 103 radiation oncologists and 22 
residents, representing 20 out of 21 RT departments in the 
Netherlands. Factors that were most often reported with 
regard to influencing the chosen RT schedules were patient 
related factors, like performance status, prognosis, patient's 
comfort and patient's choice. Late toxicity and the 
availability of linear accelerators were less contributing to 
the chosen RT schedules. In the patient cases there was a 
wide range in preferred RT schedules, however the most 
often chosen schedules were: 1x 8 Gy for hematemesis 
(esophageal bleeding 37% 1x8 Gy and bleeding of the stomach 
34% 1x8 Gy), 1x8 Gy and 5x 4 Gy (resp. 31% and 30%) for 
hemoptysis, 5x4 Gy (39%) for hematuria and 5x5 Gy (41%) in 
case of rectal bleeding. In case of vaginal bleeding 1x8 Gy, 
5x4 Gy and 10-13x3 Gy all represented about 20% of chosen 
RT schedules. Brachytherapy was rarely chosen as the 
preferred technique. Most respondents expected a response 
rate of 70 to 80%, a quick response within a few weeks and a 
response duration lasting for several weeks to months.  
Conclusions: There is a large range in RT schedules used for 
the treatment of bleeding tumors in the Netherlands. Most 
often a single fraction was chosen (35% of all cases), followed 
by a 5-fraction schedule (30% of all cases). The choice of an 
RT schedule was mainly influenced by patient related 
factors. Further research concerning the effectiveness of the 
various schedules is recommended. 
    
EP-1290   
Effectiveness of RT for metastatic spinal cord compression 
in patients with short life expectancy 
A. Giraldo Marin1, S. Benavente1, M. Ramos1, R. Vergés1, O. 
Coronil1, L.M. Arbelaez1, X. Maldonado1, M. Altabas1, M. 
Mollá1, V. Reyes1, B. Navalpotro1, J. Giralt1 
1Hospital Universitario Vall d'Hebron, Radiotherapy 
Oncology, Barcelona, Spain  
 
Purpose/Objective: Radiotherapy is an effective treatment 
for metastásica spinal cord compression (MSCC). It is unclear 
if it remains useful in patients with limited survival. This 
study analyzed the effect of radiotherapy for MSCC among 
patients with short life expectancy in an academic cancer 
center. 
Materials and Methods: A prospective evaluation of all 
patients diagnosed with MSCC and estimated short life 
expectancy by the Rades prognostic score that were treated 
with RT was conducted between February 2013 and August 
2014. Single 8 Gy fraction was recommended but the final 
decision to use multiple fraction was made by the treating 
physician. Pain, ambulatory status and sphincter control were 
recorded before and after RT and related to outcome. Pain 
relief was evaluated following the International Bone 
Metastases Consensus Working Party Guidelines. Ambulatory 
status was evaluated with the Frankel scale. Presence of 
bone fracture and spinal instability (SINS score) were 
recorded. 
Results: 56 patients were diagnosed with MSCC during this 
period and 44 were included in this analysis. 39% of patients 
had primary lung tumors and 52% had unfavourable 
histologies. 39% had bone fracture and spinal instability was 
present in 16%. 70% were treated with single 8 Gy fraction. 
31% did not complete RT treatment in the non-8 Gy cohort. 
Median overall survival was 1,4 months. Before RT, the mean 
± sd pain intensity score was 7±2. The proportion showing a 
pain response in the 8 Gy cohort was 35%, 23%, 14%, 0% at 2 
weeks, 1, 2 or 3 months post-RT while it was 15%, 0%, 0%, 0% 
in the non-8 Gy cohort. Towards death, pain intensity score 
decreased to 4 in responders (28%), whereas in non-
responders no change was observed. 61% (8 Gy) vs 46% (non-8 
Gy) were ambulatory before RT. Following RT, non-
ambulatory to ambulatory state occured in 10% (8 Gy) vs 18 % 
(non-8 Gy), whereas ambulatory progressed to non-
ambulatory in 7% (8 Gy) vs 18 % (non-8 Gy). 68% (8 Gy) vs 46% 
(non-8 Gy) maintained sphincter control before RT. Following 
RT, non-preserved to preserved state occurred in 10% (8 Gy) 
vs 18% (non-8 Gy), whereas preserved progressed to non-
preserved in 3.5% (8 Gy) vs 9% (non-8 Gy). Median survival 
was 1.9 (8 Gy) vs 0.8 (non-8 Gy) months for Rades group I, 
and 1.5 (8 Gy) vs 3 (non-8 Gy) months for Rades group II. 71% 
of patients in the 8 Gy cohort spent <5% of their remaining 
lifetime on treatment (81%, ≤10%; 6%, ≥25%) while 46% of 
patients in the non-8 Gy cohort spent ≥30% (15%, >80%; 23%, 
≤10%). 
Conclusions: Pain responded in about one third of patients 
diagnosed with MSCC and short life expectancy. When 
considering radiotherapy, single fractions should be 
preferred.  
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Purpose/Objective: Bone metastases are the most common 
cause of cancer pain requiring treatment. Radiotherapy (RT) 
is able to control symptoms up to 90% of cases. Many 
prospective and randomized trials have compared the 
effectiveness of shorter schedules in the treatments of 
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uncomplicated bone metastases. Actually, no evidence based 
recommendations are available for the treatment of 
complicated bone metastases. This study was conducted to 
evaluate the effectiveness in term of symptom control of a 
SHort course Accelerated RadiatiON therapy (SHARON study) 
in the treatment of patients with complicated bone 
metastases. 
Materials and Methods: A phase II clinical trial was designed. 
Patients with complicated bone metastases metastases, and 
Eastern Cooperative Oncology Group (ECOG) performance 
status < 3 were included. Treatment was delivered in two 
days with a twice daily fractionation and at least an eight 
hour interval at 20 Gy (5 Gy per fraction). The primary 
endpoint was the assessment of efficacy in terms of pain 
relief. 
Results: Characteristics of the 25 enrolled patients were: 
male/female: 14/11; median age: 65 years (range, 45 to 85 
y). The site of the primary tumor was: lung (36%), breast 
(32%), prostate (12%), kidney (8%), rectum (4%), thyroid (4%), 
and uterus (4%). All patients had pain at the time of 
treatment. Three weeks after treatment, the response of 
pain was evaluated by visual analogue scale (VAS). 23 of the 
25 symptomatic patients had improvement or resolution of 
pain based (overall response rate to the symptom: 92.5% CI 
0.95: 68.68% - 99.13). Specifically, 8 patients (32%) had 
complete resolution of pain, 15 patients (60%) had a partial 
response and 2 patients (8%) remained stable. A statistically 
significant reduction in pain assessed by VAS, was recorded 
(pre-treatment vs. post-treatment mean VAS = 5.9±2.6 vs. 
2.7±2.5; p = 0.039). Only 1 patient required retreatment at 
12 months. In addition, 18 of the 25 patients (72%) showed 
improvement or stability ECOG. Only acute toxicities of grade 
1 and 2 were recorded: skin G1 =16%, hematological (anemia) 
G1 = 4%, gastro-intestinal G1 (diarrhea) = 4%, gastrointestinal 
(nausea and vomiting) G2 =8%. 
Conclusions: Short course accelerated radiotherapy of 20 Gy 
BID in two consecutive days is effective in term of symptoms 
relief. These results justify a phase III comparison against the 
standard-of-care in these patients’ population (30 Gy in 10 
fractions). 
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Purpose/Objective: Recent technology of diagnosis has 
increased prevalence of oligometastatic patients. 
Stereotactic body radiotherapy (SBRT) to oliogometastases 
showed outstanding local control but also promising overall 
survival. Though liver oliogmetastses is a most common site 
for surgery, above 70% of these patients are unresectable. An 
effective and safe local modality option is necessary for 
these patients. We analyzed outcomes and toxicity for 
patients with liver oligometastases treated by SBRT from 
variable tumors. 
Materials and Methods: Seventy-two patients with liver 
oligometastases from 2002 to 2013 were treated by SBRT 
consecutively. Among them, 17 patients excluded; un-
controllable distant metastases in 9 patients and immediate 
follow-up loss after treatment in 8 patients. A total of 55 
patients with 77 lesions were analyzed retrospectively. 
Primary lesion of all patients was controlled, the patients 
with stable lesions in another site in 28 patients. The most 
common primary organ was colon in 36 patients followed by 
the stomach 6 patients, and other 13 patients. The tumor 
volume was calculated by sum of total GTV. The median 
volume was 20 cc (0.7-721.2 cc). Thirty-eight (69%) of the 
patients had a single metastatic lesion. Total SBRT dose was 
from 30 to 60 Gy (median 48 Gy) by 3-4 fractions. Thirty-nine 
(72%) of the patients received chemotherapy as part of their 
primary treatment. Toxicity was evaluated by Common 
Toxicity Criteria for Adverse Events Version 4.0 Grading 
scale. 
Results: The 2 and 5-year overall survival rate was 56% and 
20%, respectively. Actuarial 2 year local control and 
progression free survival rate were 60% and 22%, 
respectively. Grade 1-2 fatigue, nausea, and vomiting were 
the most common adverse events, and no grade 3 and higher 
adverse events were observed. By multivariate analysis 
according to survival, other visible lesion was a statistically 
significant factor. 
Conclusions: SBRT for liver oligometastases seems to be safe. 
High SBRT dose is correlated with high local control. To 
obtain survival gain through SBRT among patients with 
oligorecurrence, criteria of optimal candidate is mandatory. 
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Purpose/Objective: 8 Gy single fraction (flash) conventional 
external beam radiation therapy is the most commonly 
administered single fraction dose and is considered the 
standard treatment for uncomplicated bone metastases. 
However, its efficacy is uncertain in patients with bone 
metastases involving the adjacent soft tissues. Aim of the 
study was to evaluate the flash efficacy in terms of pain 
control for this particular patient setting. 
Materials and Methods: An observational study of patients 
treated with Radiotherapy for bone metastases was 
conducted from January 2003 to December 2010 in our 
Department. The study included patients with painful bone 
metastases of any primary sites and any ECOG performance 
status < 4. Eight Gray single fraction conventional external 
beam radiation therapy (3DCRT) was administered. Patients 
were evaluated for pain with visual-analogue scale (VAS) 
before and 3 weeks after irradiation. Pain response was 
